Apellis Medical Hub https://validator.w3.org/feed/docs/rss2.html Pegcetacoplan for 52 weeks maintained proteinuria reduction regardless of immunosuppressant use or nephrotic range proteinuria at baseline: VALIANT subgroup analysis (NKF SC Medical Symposium 2026 C3G) Home Earlier Treatment Yields Better Outcomes: 5 Years of Pegcetacoplan Treatment for Geographic Atrophy Secondary to AMD (Macula Society 2026 GA) NKF Southern California Medical Symposium 2026 C3G PNH Congress Presentations Paroxsymal Nocturnal Hemoglobinuria (PNH) Pegcetacoplan population pharmacokinetic and exposure-response in pediatric and adult patients with C3G and primary immune-complex membranoproliferative glomerulonephritis (ASCPT 2026 C3G) C3 Glomerulopathy (C3G) and Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) Clinical efficacy of pegcetacoplan versus iptacopan in patients with C3 glomerulopathy: Indirect treatment comparisons (SWNC 2026 C3G) Pegcetacoplan for 52 weeks results in sustained proteinuria reduction to remission (≤0.5 g/g) and normalization (≤0.2 g/g): Phase 3 VALIANT trial (SWNC 2026 C3G) Pegcetacoplan for 52 weeks maintained proteinuria reduction regardless of immunosuppressant use or nephrotic range proteinuria at baseline: VALIANT subgroup analysis (SWNC 2026 C3G) Southwest Nephrology Conference (SWNC) 2026 C3G Cutting Edge of Transplantation (CEoT) 2026 C3G Pegcetacoplan for Posttransplant Patients with Complement 3 Glomerulopathy or Primary (Idiopathic) Immune-Complex Membranoproliferative Glomerulonephritis (CEoT 2026 C3G) American Society for Clinical Pharmacology and Therapeutics (ASCPT) 2026 C3G Macula Society 2026 GA AI in GA: Learnings From the Pegcetacoplan Clinical Program (Macula Society 2026 GA) Geographic Atrophy GA Can Visual Acuity be Estimated from Multimodal Imaging of Geographic Atrophy in Age-related Macular Degeneration? (Macula Society 2026 GA) Fellow Eye Analysis in Bilateral GA due to AMD: Long-term Data from the OAKS, DERBY, and GALE Studies (Macula Society 2026 GA) Factors Affecting Disease Progression and Vision Loss in Geographic Atrophy: Findings from OAKS and DERBY (Macula Society 2026 GA) Retrospective Comparative Analysis of Demographic and Clinical Profiles in Pegcetacoplan-Treated and Untreated Patients With Geographic Atrophy (Macula Society 2026 GA) Real-World Pegcetacoplan and Anti-VEGF Treatment Patterns Among Patients With Geographic Atrophy (Macula Society 2026 GA) Low Risk For Meningococcal Infections With Systemically Administered Pegcetacoplan, a C3 and C3b Inhibitor (AAMDSIF BMF 2026 PNH) OCT-F: AI-Enabled Retinal Function from Structural OCT – Results from OAKS and DERBY (Macula Society 2026 GA) International AAMDSIF Bone Marrow Failure Disease Scientific Symposium (AAMDSIF BMF) 2026 PNH Clinical efficacy of pegcetacoplan versus iptacopan in patients with C3 glomerulopathy: Indirect treatment comparisons (NKF SC Medical Symposium 2026 C3G) Low Risk For Meningococcal Infections With Systemically Administered Pegcetacoplan, a C3 and C3b Inhibitor (THSNA 2026 PNH) Pegcetacoplan for Posttransplant Patients with Complement 3 Glomerulopathy or Primary (Idiopathic) Immune-Complex Membranoproliferative Glomerulonephritis (WTC 2025 C3G) World Transplant Congress (WTC) 2025 C3G Manuscripts Pegcetacoplan for 52 weeks results in sustained proteinuria reduction to remission (≤0.5 g/g) and normalisation (≤0.2 g/g): Phase 3 VALIANT trial (NKF SC Medical Symposium 2026 C3G) (Relink to conference page) Consistent benefits of pegcetacoplan treatment in PNH patients with and without a history of aplastic anemia in the real world: Analysis of the ongoing Phase 4 COMPLETE observational study (ASH 2025 PNH) Thrombosis and Hemostasis Summit of North America (THSNA) 2026 PNH American Society of Nephrology (ASN) Kidney Week 2025 C3G Pegcetacoplan for adolescents and adults with C3 glomerulopathy or primary immune-complex membranoproliferative glomerulonephritis: enrollment status of the VALE extension (ASN 2025 C3G) Pegcetacoplan for 52 weeks results in sustained proteinuria reduction to remission (≤0.5 g/g) and normalisation (≤0.2 g/g): Phase 3 VALIANT trial (NKF SC Medical Symposium 2026 C3G) AI in GA: Learnings From the Pegcetacoplan Clinical Program (Hawaiian Eye and Retina 2026 GA) American Society of Hematology (ASH) 2025 PNH Early Results From the Ongoing Pegcetacoplan Silo of the International Paroxysmal Nocturnal Hemoglobinuria Interest Group Registry (ASH 2025 PNH) Real-world clinical characteristics and treatment outcomes in PNH patients prescribed pegcetacoplan across Europe, the United States and Canada (ASH 2025 PNH) Pegcetacoplan Versus Iptacopan for the Treatment of Patients with C3 Glomerulopathy: Indirect Treatment Comparisons (ASN 2025 C3G) “Tiredness…That’s the main thing, this is why I work part time.”: A thematic analysis of patient perspectives on care and unmet needs in C3G and primary IC-MPGN (ASN 2025 C3G) Learnings From OAKS and DERBY: Patient Selection Based on Risk Factors for Geographic Atrophy Progression and Vision Loss (Hawaiian Eye and Retina 2026 GA) Pegcetacoplan for 52 weeks results in sustained proteinuria reduction to remission (≤0.5 g/g) and normalization (≤0.2 g/g): Phase 3 VALIANT trial (ASN 2025 C3G) Pegcetacoplan for 52 weeks maintained proteinuria reduction regardless of immunosuppressant use or nephrotic range proteinuria at baseline: VALIANT subgroup analysis​ (ASN 2025 C3G) Human factors validation of a pegcetacoplan on-body injector demonstrates ease of use by adolescents with C3 glomerulopathy or primary immune-complex membranoproliferative glomerulonephritis (ASN 2025 C3G) Pegcetacoplan for 52 weeks maintains proteinuria reduction and eGFR stabilization for pediatric patients: Phase 3 VALIANT subgroup analysis (ASN 2025 C3G) American Academy of Ophthalmology (AAO) 2025 GA Impact of AREDS Oral Micronutrient Supplementation on Geographic Atrophy Progression: Insights from the Phase 3 OAKS and DERBY Trials (AAO 2025 GA) Hawaiian Eye and Retina 2026 GA